TPO receptor agonist for chronic idiopathic thrombocytopenic purpura

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 7, 2011, Pages

  Zeng, Yan ^a   Duan, Xin ^a   Xu, Jiajun ^a   Ni, Xun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; ELTROMBOPAG; FC RECEPTOR; HYBRID PROTEIN; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; ROMIPLOSTIM; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

CHRONIC DISEASE; DRUG POTENTIATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

BENZOIC ACIDS; CHRONIC DISEASE; HUMANS; HYDRAZINES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN;

EID: 79960989219     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008235.pub2     Document Type: Review

References (49)

1. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. New England Journal of Medicine 2006;355:1672-81.
2. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine 2007;357:2237-47.
3. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641-8.
4. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377:393-402.
5. George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. British Journal of Haematology 2009;144(3):409-15.
6. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403.
7. Pullarkat VA, Gernsheimer TB, Wasser JS, Newland A, Guthrie TH, Joost Th. M. de Wolf, et al. Quantifying the reduction in immunoglobulin (Ig) use over time in patients with chronic immune thrombocytopenic purpura (ITP) receiving romiplostim (AMG531). American Journal of Hematology 2009;84:538-40.
8. George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. British Journal of Haematology 2009;144(3):409-15.
9. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403.
10. Pullarkat VA, Gernsheimer TB, Wasser JS, Newland A, Guthrie TH, Joost Th. M. de Wolf, et al. Quantifying the reduction in immunoglobulin (Ig) use over time in patients withchronic immune thrombocytopenic purpura (ITP) receiving romiplostim (AMG531). American Journal of Hematology 2009;84:538-40.
11. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. New England Journal of Medicine 2010;363:1889-99.
12. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113(10):2161-71.
13. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009;114(18):3748-56.
14. Safety and efficacy study of romiplostim to treat ITP in pediatric subjects. Ongoing study July 2007.
15. P3 study to evaluate efficacy and safety of AMG 531 in thrombocytopenic Japanese subjects with immune (idiopathic) thrombocytopenic purpura. Ongoing study October 2007.
16. Efficacy and safety study of eltrombopag in pediatric patients with thrombocytopenia from chronic ITP (PETIT). Ongoing study September 2009.
17. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Annals of Internal Medicine 2007;146:25-33.
18. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Canadian Medical Association Journal 2004;170(4):477-80.
19. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine 2007;357:2237-47.
20. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641-8.
21. Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003;102:887-95.
22. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. New England Journal of Medicine 2002;346:995-1008.
23. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura(ITP). Blood 2005;106:2244-51.
24. Cooper N, Stasi R, Cunningham-Rundles, Feuerstein MA, Leonard JP, Amadori S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology 2004;125:232-9.
25. Debili N, Wendling F, Cosman D, Titeux M, Florindo C, Dusanter-Fourt I, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995;85:391-401.
26. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009).The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
27. Elbourne DR, Altmanb DG, Higginsc JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
28. Erickson-Miller C, Delorme E, Iskander M, Giampa L, Hopson CB, Luengo JI, et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist. Blood 2004;104:abstract 2909.
29. Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Stark K, Giampa L, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Experimental Hematology 2005;33:85-93.
30. George JN, Raskob GE. Idiopathic thrombocytopenic purpura: diagnosis and management. American Journal of the Medical Sciences 1998;316:87.
31. George JN. Treatment options for chronic idiopathic (immune) thrombocytopenic purpura. Seminars in Hematology 2000;37:31-4.
32. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009).The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
33. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109:4739-41.
34. Karpaktin S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet 1997;349:1531-6.
35. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104(9):2623-34.
36. Kuter DJ. New thrombopoietic growth factors. Blood 2007;109:4607-16.
37. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403.
38. Kuter DJ. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. European Journal of Haematology 2008;80 (Suppl 69):9-18.
39. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009).The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
40. McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. International Journal of Hematology 2005;91:94-9.
41. Newland A, Caulier MT, Kappers-Klune M, Schipperus MR, Lefrere F, Zwagingu JJ, et al. An open-label, unit dose-finding study of AMG 531 a novel, thrombopoiesis stimulating peptidbody, in patients with immune thrombocytopenic purpura. British Journal of Haematology 2006;135:547-53.
42. Panzer S. Novel approaches in management of immune thrombocytopenia. Thrombosis Research 2009;123(Suppl 2):S51-5.
43. Provan D, Newland A, Norfolk D, Bolton-Maggs P, Lilleyman J, Greer I, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. British Journal of Haematology 2003;120(4):574-96.
44. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
45. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Lancet 2010;152:726.
46. Solar GP, Kerr WG, Zeigler FC, Hess D, Donahue C, Sauvage FJ, et al. Role of c-Mpl in early hematopoiesis. Blood 1998;92:4-10.
47. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
48. Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Annals of Internal Medicine 2004;140:112-20.
49. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clinical Pharmacology & Therapeutics 2004;76:628-38.